Radiopharmaceutical Compensation Benchmark Report: U.S. Market View
This is a planning and validation tool for US radiopharmaceutical leadership hiring, not a salary survey. It models base-salary planning ranges across six hubs, four functions and three seniority levels, with Boston - Cambridge as the reference point. Its premise is that senior radiopharma hires stall on misaligned scope and compensation assumptions, not on candidate interest.
What this report answers
- Is our current budget credible for the leadership scope we are actually defining?
- Why can radiopharma leadership pay not be benchmarked from general biotech or pharma data?
- Which US hubs are the ranges built for, and what happens where our site is not listed?
- Are we over-loading a role without adjusting compensation to match the execution burden?
- What sits outside base salary at this level, and how much does it move the total?
- Which functions are likely to tighten further as programmes mature into 2026?
20-60%+
the amount the briefing attributes to bonus, equity, sign-on and relocation components on top of base salary at senior radiopharma level - which is why every range in the tables is base only.
What the analysis establishes
What the tables actually cover
The benchmark is built around four leadership functions - CMC and technical operations, operations and manufacturing, quality, and CMC or radiopharma regulatory - each modelled at director, senior director and vice president level. Six US hubs are presented as standalone tables. Every figure is base salary only, expressed in USD, with an adjusted minimum, typical and maximum for each combination.
Why general biotech data does not transfer
The report sets out three structural distortions specific to the modality: overlapping regulatory regimes that narrow the viable pool and raise the cost of a mis-hire, roles titled and budgeted for steady-state operations while the work is genuinely build-phase, and leadership talent that is far more concentrated than radiopharmaceutical activity itself. Each one is explained in terms of what it does to hiring outcomes.
How the hub adjustment works
Boston - Cambridge is the baseline reference hub, and the other regions are derived from it using published multipliers. The report is explicit that the multiplier is a normalisation mechanism rather than a claim of precision: it exists to keep roles and locations internally consistent, not to assert that any single number is a market-clearing salary.
Geographies deliberately left out
Southern California, the Pacific Northwest and the Research Triangle are not given standalone tables. The report explains which of the presented hubs each typically aligns with in practice, and states plainly that for any unlisted geography the tables are directional only, to be adjusted for role scope and execution risk rather than read literally.
What the ranges exclude
Bonus, equity and long-term incentives, sign-on and retention awards, and relocation or tax equalisation all sit outside the figures shown. The report quantifies how much those components typically add at senior level in radiopharma, and directs that they be modelled separately rather than assumed inside the base ranges.
Where pressure is expected to build into 2026
The closing outlook identifies which senior functions it expects to remain structurally constrained, which category of operational leader it expects to keep commanding a premium, and what it expects geographic spread between hubs to do before it settles. It also names the three executive questions the benchmark is designed to answer before a search is launched or reset.
How it was built
A blended model, described openly as such. Three inputs are combined: published base-salary ranges from radiopharmaceutical and adjacent RLT roles taken from company disclosures, job advertisements and regulatory filings, which anchor the director and senior director levels; aggregated and anonymised compensation expectations observed across ProGen Search leadership hiring activity, including stated candidate expectations and accepted against declined offer dynamics; and comparative inference from advanced biologics, cell and gene therapy and ADC manufacturing leadership where radiopharma-specific data is thin. No individual-level data is disclosed. The report labels every figure as a modelled planning range rather than a survey average.
Written for executive teams, people leaders and boards at radiopharmaceutical and isotope-adjacent organisations setting hiring budgets, scoping senior roles, or resetting a search that has stalled.
Contents
- Executive context
- Purpose of this benchmark
- Why radiopharma compensation behaves differently
- How to read the compensation tables
- Geographic coverage and exclusions
- Methodology and data sources
- How this benchmark should be used, and its limitations
- Looking into 2026
- Compensation tables by hub, function and level
Regulators referenced
FDA, NRC
The full 11-page briefing is free. Tell us where to send it and it downloads immediately.
The State of Radiopharmaceuticals 2026
This benchmark prices the roles. The flagship radiopharma report covers the sector those roles are being hired into - structure, named operators and where the constraints sit.
See the full report →